Core Insights - Eton Pharmaceuticals has launched Galzin (zinc acetate) capsules, the only FDA-approved zinc therapy for Wilson disease, aimed at expanding patient access to this critical treatment [1][8] - The company offers a $0 co-pay for all eligible patients and has established the Eton Cares patient support services to facilitate access to Galzin [1][3] Company Overview - Eton Pharmaceuticals focuses on developing and commercializing treatments for rare diseases, currently offering seven commercial products and four additional candidates in late-stage development [8] Product Launch Details - Galzin is now available exclusively through Optime Care, a specialty pharmacy that will administer the Eton Cares Program, providing various support services including prescription fulfillment and financial assistance [3][4] - The launch aims to address historical challenges in availability and affordability, encouraging patients to use the approved medication instead of unapproved alternatives [2] Patient Support Initiatives - Eton Cares will ensure that eligible patients have access to Galzin with comprehensive support services, including educational resources and insurance benefits investigation [3][2] - The program is designed to enhance awareness and access to Galzin within the Wilson disease community [2] Clinical Information - Galzin is indicated for the maintenance treatment of Wilson disease patients who have been initially treated with a chelating agent [8] - Patients are advised to take Galzin on an empty stomach and must be clinically monitored for the adequacy of therapy [10]
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules